Quick Answer
ANI PHARMACEUTICALS INC reported Total Assets of $1.44 billion for the year ending 2025.
- ANI PHARMACEUTICALS INC showed an increase of +12.1% in Total Assets from 2024 to 2025.
- This data is from ANI PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $42.76 million | Q3 2011: $74.89 million | Q1 2012: $54.57 million | Q2 2012: $47.29 million | Q3 2012: $43.21 million | Q1 2013: $35.36 million | Q2 2013: $41.66 million | Q3 2013: $43.29 million | Q1 2014: $96.65 million | Q2 2014: $95.42 million | Q3 2014: $107.64 million | Q1 2015: $265.99 million | Q2 2015: $270.12 million | Q3 2015: $283.28 million | Q1 2016: $291.59 million | Q2 2016: $308.00 million | Q3 2016: $319.38 million | Q1 2017: $357.14 million | Q2 2017: $359.22 million | Q3 2017: $370.47 million | Q1 2018: $418.02 million | Q2 2018: $424.18 million | Q3 2018: $439.44 million | Q1 2019: $434.39 million | Q2 2019: $446.91 million | Q3 2019: $456.78 million | Q1 2020: $482.23 million | Q2 2020: $465.39 million | Q3 2020: $462.58 million | Q1 2021: $463.84 million | Q2 2021: $480.16 million | Q3 2021: $470.45 million | Q1 2022: $744.85 million | Q2 2022: $751.33 million | Q3 2022: $739.11 million | Q1 2023: $765.22 million | Q2 2023: $859.34 million | Q3 2023: $889.91 million | Q1 2024: $914.52 million | Q2 2024: $920.75 million | Q3 2024: $1.29 billion | Q1 2025: $1.29 billion | Q2 2025: $1.34 billion | Q3 2025: $1.41 billion.
- Over the full 16 years of available data (2010 to 2025), ANI PHARMACEUTICALS INC's Total Assets has grown by 3,117.5%.
- Historical annual values: Fiscal year 2025: $1.44 billion | Fiscal year 2024: $1.28 billion | Fiscal year 2023: $904.42 million | Fiscal year 2022: $760.09 million | Fiscal year 2021: $771.60 million | Fiscal year 2020: $461.19 million | Fiscal year 2019: $456.79 million | Fiscal year 2018: $430.60 million | Fiscal year 2017: $412.14 million | Fiscal year 2016: $322.86 million | Fiscal year 2015: $285.27 million | Fiscal year 2014: $259.56 million | Fiscal year 2013: $44.50 million | Fiscal year 2012: $13.75 million | Fiscal year 2011: $62.38 million | Fiscal year 2010: $44.77 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: